The main objective of this study is to identify the sequences followed and delays encountered by each anticancer product between the country of origin and the delivery point at the main anti-cancer center in Algeria the CPMC. A second objective is to evaluate the effects of the introduction of the special procedure called “temporary authorization of a use” (TAU). METHODS:

A sample of Oncology drugs was determined for the period 1999–2013. These oncology products were approved by the European medicines agency. A sample of 60 products was selected.

The main sequences studied were:

Date of market authorization by EMA and Algeria, date of first purchase by the central pharmacy for hospitals (responsible for procurement of inpatients drugs) and date of registration of the drug on the list of oncology products used by the CPMC. The sequences and  time periods have been identified but also analyzed using a regression model.

Between 1999-2007 (pre-ATU) it was 48 months and 25 month for 2007-2012 (post- ATU).

The high product prices have been felt as a serious obstacle to large introduction and access, moreover we identified a significant differences in term of the early access between the companies implemented in the local market and the companies who set up a liaison offices in Algeria